ATE513557T1 - Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens - Google Patents

Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens

Info

Publication number
ATE513557T1
ATE513557T1 AT06843990T AT06843990T ATE513557T1 AT E513557 T1 ATE513557 T1 AT E513557T1 AT 06843990 T AT06843990 T AT 06843990T AT 06843990 T AT06843990 T AT 06843990T AT E513557 T1 ATE513557 T1 AT E513557T1
Authority
AT
Austria
Prior art keywords
tissues
acid content
diseases associated
deoxyribonucleic acid
human diseases
Prior art date
Application number
AT06843990T
Other languages
German (de)
English (en)
Inventor
Georgy Viktorovich Tets
Original Assignee
Cls Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cls Therapeutics Ltd filed Critical Cls Therapeutics Ltd
Application granted granted Critical
Publication of ATE513557T1 publication Critical patent/ATE513557T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT06843990T 2006-11-28 2006-11-28 Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens ATE513557T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2006/000642 WO2008066403A1 (fr) 2006-11-28 2006-11-28 Procédé de traitement de maladies humaines accompagnées d'une teneur plus élevée d'adn dans des espaces intercellulaires et préparation médicamenteuse destinée à sa mise en oeuvre

Publications (1)

Publication Number Publication Date
ATE513557T1 true ATE513557T1 (de) 2011-07-15

Family

ID=39468110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06843990T ATE513557T1 (de) 2006-11-28 2006-11-28 Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens

Country Status (9)

Country Link
US (1) US8871200B2 (OSRAM)
EP (1) EP2095825B8 (OSRAM)
JP (1) JP5372769B2 (OSRAM)
KR (1) KR20090087095A (OSRAM)
AT (1) ATE513557T1 (OSRAM)
ES (1) ES2369547T3 (OSRAM)
IL (1) IL199005A (OSRAM)
PL (1) PL2095825T3 (OSRAM)
WO (1) WO2008066403A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
ES2369547T3 (es) 2006-11-28 2011-12-01 Cls Therapeutics Limited Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento.
IN2012DN02381A (OSRAM) 2009-09-18 2015-08-21 Nippon Kayaku Kk
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
NZ733912A (en) 2015-01-04 2023-04-28 Protalix Ltd Modified dnase and uses thereof
CN108289932A (zh) * 2015-05-22 2018-07-17 D·D·格恩金 胞外dna作为神经变性的治疗靶点
BR112018007017B1 (pt) 2015-10-07 2023-11-28 Novozymes A/S Composição detergente, construto de ácido nucleico ou vetor de expressão, uso de um polipeptídeo, célula hospedeira recombinante e método para produzir o polipeptídeo
WO2018197547A1 (en) 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
WO2019143272A1 (en) 2018-01-16 2019-07-25 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (dnase) activity
WO2020006389A1 (en) * 2018-06-29 2020-01-02 Viktor Veniaminovich Tets Compositions for modulating gut microbiota
US20200046809A1 (en) * 2018-08-07 2020-02-13 Bradley G. Thompson Methods for regulating endogenous production of dnase1
US12478571B2 (en) 2018-12-17 2025-11-25 Pontis Biologics, Inc. Enzyme based compositions and methods for removing dental calculi
WO2020131952A1 (en) * 2018-12-17 2020-06-25 Mynarcik Dennis C Compositions and methods for removing dental calculi
US20230416707A1 (en) 2020-10-07 2023-12-28 Protalix Ltd. Long-acting dnase
WO2022249170A1 (en) * 2021-05-24 2022-12-01 Peri-Ness Technologies Ltd Therapeutic regimen with dnase

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3224942A (en) 1962-01-15 1965-12-21 Rorer Inc William H Anti-inflammatory, anti-edema and anti-thrombi drug
US3324002A (en) 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
JPS5826822A (ja) * 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS61293927A (ja) 1986-06-18 1986-12-24 Kaken Pharmaceut Co Ltd 肝臓疾患予防治療剤
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
ATE358176T1 (de) * 1988-12-23 2007-04-15 Genentech Inc Menschliche dnase
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DE4024530A1 (de) 1990-08-02 1992-02-06 Klinger & Co Dr Verfahren zur bekaempfung von viren
FR2666096B1 (fr) * 1990-08-21 1993-12-31 Sfri Sa Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu.
JPH06510036A (ja) 1991-08-16 1994-11-10 バイカル・インコーポレイテッド 嚢胞性線維症の治療のための組成物および方法
US5484589A (en) * 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
NZ299257A (en) 1992-06-08 2000-08-25 Genentech Inc Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
WO1995000170A1 (en) 1993-06-24 1995-01-05 Rufeld, Inc. Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i
CH686982A5 (fr) * 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
RU2099080C1 (ru) 1994-02-11 1997-12-20 Дмитрий Иванович Финько Способ предотвращения развития рака
WO1995023613A1 (en) 1994-03-04 1995-09-08 Genentech, Inc. PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
DE69533987T2 (de) * 1994-05-20 2006-03-16 Hisamitsu Pharmaceutical Co., Inc., Tosu Protein oder polypeptid, verfahren zur seiner herstellung und entsprechende zwischenprodukte
WO1997028266A1 (en) 1996-02-05 1997-08-07 Genentech, Inc. Human dnase resistant to actin inhibition
US6156504A (en) * 1996-03-15 2000-12-05 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6524578B1 (en) 1996-07-10 2003-02-25 Scott E. Tackett Use of nuclease to reduce wrinkles and discolorations in humans
US6455250B1 (en) * 1997-12-11 2002-09-24 The Regents Of The University Of California Endonuclease compositions and methods of use
RU2227029C2 (ru) 1998-07-16 2004-04-20 Рисерч Дивелопмент Фаундейшн Новые днк-расщепляющие противоопухолевые агенты
US6465177B1 (en) * 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
IL143328A0 (en) 1998-11-25 2002-04-21 Genetica Inc Methods and reagents for increasing proliferative capacity and preventing replicative senescence
ATE369419T1 (de) * 1999-08-17 2007-08-15 Sei-Ichi Tanuma Deoxyribonuklease, dafür kodierendes gen und verfahren
US6428785B1 (en) * 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
WO2001074905A1 (en) 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
RU2202109C1 (ru) 2001-08-03 2003-04-10 Научно-исследовательский институт неврологии РАН Способ выявления степени нарушения реологических свойств крови
RU2207876C1 (ru) 2001-11-08 2003-07-10 Ткаченко Виталий Васильевич Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия
ES2527096T3 (es) * 2002-02-18 2015-01-20 Ockham Biotech Limited Combinación de ADNasa I y glucosaminoglucanos para su uso en limpieza de ADN extracelular
RU2207676C1 (ru) 2002-04-24 2003-06-27 ООО "Предприятие "Контакт-1" Плоский радиолокационный отражатель
DE10221194B4 (de) 2002-05-13 2005-02-10 Fryda, Waltraud, Dr.med. Hyaluronidasehaltiges Hautpflegemittel
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
RU2239442C1 (ru) 2003-05-05 2004-11-10 Красноярская государственная медицинская академия Способ профилактики внутриутробных инфекций у детей
RU2269359C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
RU2269356C2 (ru) * 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) * 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
RU2269358C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
WO2005007187A1 (en) 2003-07-14 2005-01-27 Viktor Veniaminovich Tets Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
WO2005004904A1 (en) 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants)
RU2239404C1 (ru) 2003-09-17 2004-11-10 Бессонов Дмитрий Михайлович Способ профилактики старения организма человека
RU2269357C2 (ru) 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ замедления наступления болезненных состояний, связанных с увеличением возраста человека
RU2267329C2 (ru) 2004-03-12 2006-01-10 Дмитрий Дмитриевич Генкин Способ лечения заболеваний, сопровождающихся изменениями качественного и/или количественного состава внеклеточной днк крови (варианты)
JP2007532666A (ja) * 2004-04-14 2007-11-15 アヴィリッド インコーポレーテッド ウイルス核酸を対象とした修飾ヌクレアーゼを用いた組成物及びウイルス性疾患の予防並びに治療方法
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
AU2006271181B2 (en) * 2005-07-18 2012-07-12 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
RU2308968C2 (ru) 2005-07-19 2007-10-27 Дмитрий Дмитриевич Генкин Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации
EP2086642B1 (en) * 2006-10-18 2014-06-25 Periness Ltd. Dnase for the treatment of male sub-fertility
ES2369547T3 (es) 2006-11-28 2011-12-01 Cls Therapeutics Limited Procedimiento para el tratamiento de enfermedades humanas asociadas con un contenido elevado del ácido desoxirribonucleico en los espacios extracelulares de los tejidos y preparación médica para llevar a cabo dicho procedimiento.
GB0922006D0 (en) 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
US20130243794A1 (en) 2010-12-03 2013-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses

Also Published As

Publication number Publication date
EP2095825B1 (en) 2011-06-22
WO2008066403A1 (fr) 2008-06-05
KR20090087095A (ko) 2009-08-14
IL199005A0 (en) 2010-02-17
ES2369547T8 (es) 2012-01-05
EP2095825A1 (en) 2009-09-02
JP2010511039A (ja) 2010-04-08
ES2369547T3 (es) 2011-12-01
EP2095825B8 (en) 2012-03-28
EP2095825A4 (en) 2009-12-30
US8871200B2 (en) 2014-10-28
PL2095825T3 (pl) 2011-12-30
US20100061971A1 (en) 2010-03-11
JP5372769B2 (ja) 2013-12-18
IL199005A (en) 2012-04-30

Similar Documents

Publication Publication Date Title
IL199005A0 (en) Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
Alqareer et al. The effect of clove and benzocaine versus placebo as topical anesthetics
Ellingwood American materia medica, therapeutics and pharmacognosy: developing the latest acquired knowledge of drugs, and especially of the direct action of single drugs upon exact conditions of disease, with especial reference to the therapeutics of the plant drugs of the Americas
CN110151594A (zh) 一种含依克多因和透明质酸的口腔组合物及其应用
KR102705552B1 (ko) 만성 치은염의 치료 또는 경감을 위한 조성물
CN109152702A (zh) 用于化合物的局部应用的组合物
WO2008125120A2 (en) Extract of trigonella foenum-graecum
US20210154169A1 (en) Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin a for the treatment of neuropsychiatric and addictive disorders
DE602005021115D1 (de) Verfahren und zusammensetzungen zur oralen fts-abgabe
CN1669562A (zh) 筋骨康复膏及其制备方法
KR20120061185A (ko) 한방 음료 조성물 및 그 제조방법
US20060275505A1 (en) Method and composition for increasing the alkalinity of the body
CN107596355A (zh) 一种医用镇痛、消肿、退热的外用凝胶剂及其制备方法
US20090036541A1 (en) Applicator and chemical combination for better topical anesthesia
CN116747265A (zh) 一种抗老化再生配方
CN116211922B (zh) 一种助眠安神的复方精油及其制备方法与用途
US20190110512A1 (en) Food composition for relieving symptoms of viral diseases
CN100342864C (zh) 治疗顽固性痔疮的内服药
CN109432213A (zh) 一种口腔用品活性组合物，其制备方法及用途
CN102232968A (zh) 治疗脂溢性皮炎的中药外用药酒
Ghosh et al. MUCORMYCOSIS IN THE LIGHT OF AYURVEDA
Suguna et al. PHYSIOCHEMICAL EVALUATION OF PSIDIUMGUAJAVA LEAVES EXTRACT LOADED BUCCAL PATCH FOR ENHANCED MUCOSAL ABSORPTION
CN107029205A (zh) 一种具有活血化瘀、消炎镇痛作用的药剂及其制备方法
RU2006114078A (ru) Лекарственный препарат и способ лечения ревматических заболеваний
Melnik et al. Pharmacological research of the dental gel with carbon dioxide Humulus lupulus extract

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties